Sevelamer Hydrochloride Tablet, Film Coated
Product Images NDC 68462-446

6 FDA label images from Glenmark Pharmaceuticals Inc., Usa · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sevelamer Hydrochloride (NDC 68462-446). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bottle Label 400 mg

Bottle Label 400 mg
Label for Sevelamer Hydrochloride Tablets 400 mg, film-coated tablets, packaged in a container of 360 tablets. Label shows the NDC number 68462-446-26 and indicates Rx only. Manufactured by Glenmark Pharmaceuticals Limited, India, for Glenmark Pharmaceuticals Inc., USA. Storage instructions and contact information are also provided.*
FDA Label Image

Bottle Label 800 mg

Bottle Label 800 mg
Packaging label for Sevelamer Hydrochloride Tablets, 800 mg strength, film-coated. The label indicates a count of 180 tablets, Rx only, manufactured by Glenmark Pharmaceuticals Limited, India, and distributed by Glenmark Pharmaceuticals Inc., USA. Storage instructions and a barcode are also present.*
FDA Label Image

Chemical Structure

Chemical Structure
Chemical structure diagram of sevelamer hydrochloride, showing the polymeric backbone with multiple amine hydrochloride groups and hydroxyl functional groups.*
FDA Label Image

Figure 2

Figure 2
A line graph comparing the percentage of patients with a reduction of serum phosphorus by at least 1 mg/dL. The x-axis represents reduction in serum phosphorus (mg/dL) ranging from -4 to 8, with indicators for worsened increase and improved reduction from baseline. The y-axis shows the percentage of patients from 0% to 100%. Two curves are depicted: one for Sevelamer Hydrochloride and one for an Active Control, illustrating their efficacy in reducing serum phosphorus levels.*
FDA Label Image

Figure 3

Figure 3
A line chart showing phosphorus change from baseline over a 52-week study period. The x-axis represents study weeks (0 to 52), and the y-axis shows phosphorus change from baseline (-5 to 2). Two treatment groups are shown: Sevelamer Hydrochloride and Active-Control, with Sevelamer Hydrochloride consistently showing greater phosphorus reduction.*
FDA Label Image
Glenmark-logo (Glenmark Logo)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.